All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
On November 29, 2022, the GvHD Hub held a virtual symposium on the role of extracorporeal photopheresis (ECP) in the management of graft-versus-host disease (GvHD).
Here, we share the presentation given by Professor Hildegard Greinix, Medical University of Graz, Graz, AT, which considered ECP and how it works.
In this presentation, Professor Greinix details the process of ECP (Figure 1), as well as its direct and indirect effects at a cellular level, and discusses the use of ECP, alone or in combination, for both chronic and acute GvHD, and its impact on quality of life (Figure 2), referencing data and outcomes from multiple research studies.
Figure 1. The process of ECP*
ECP, extracorporeal photopheresis; GvHD, graft-versus-host disease; UVA, ultraviolet A.
*Adapted from Knobler, et al.1 Created with BioRender.com.
Figure 2. Quality of life during ECP treatment*†
ECP, extracorporeal photopheresis; SF-36, 36-item short form health survey; SoC, standard of care.
*Copyright © 2022 by Elsevier. Reproduced with permission. Jagasia M, et al. Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD Blood Adv. 2019;3(14):2218-2229. DOI: 10.1182/bloodadvances.20190001452
†The SF-36 domains of quality of life were scored from 0 to 100.
Watch or download the presentation to learn more about ECP, including:
This independent educational activity was supported by Mallinckrodt Pharmaceuticals. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
To download the slides presented, click here.Download here
Subscribe to get the best content related to GvHD delivered to your inbox